UK’s Kymab signs bispecific antibodies deal with China’s EpimAb
UK biopharma Kymab has signed a cross-licensing and development deal with Shanghai-based EpimAb Biotherapeutics to develop bispecific therapeutic antibodies against multiple targets.
Read More
